Acute hypobaric hypoxia attenuates the anti-fatigue effects of pitolisant by downregulating the expression of organic cation transporter 1 and P-glycoprotein [PDF]
Frontiers in PharmacologyObjectiveThis study investigates the effects of acute hypobaric hypoxia (HH) on the anti-fatigue properties of pitolisant and explores the underlying mechanisms.
Gang Zhao +10 more
doaj +4 more sources
Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report [PDF]
Nature and Science of Sleep, 2020 Gaia Pellitteri,1,2 Pierluigi Dolso,1 Mariarosaria Valente,1,2 Gian Luigi Gigli1– 3 1Clinical Neurology Unit, Department of Neurosciences, Udine University Hospital, Udine, Italy; 2Department of Medicine (DAME), University of Udine, Udine, Italy ...
Pellitteri G +3 more
doaj +7 more sources
Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease [PDF]
Translational PsychiatryHistamine H3 receptor (H3R) antagonists regulate histamine release that modulates neuronal activity and cognitive function. Although H3R is elevated in Alzheimer’s disease (AD) patients, whether H3R antagonists can rescue AD-associated neural impairments
Yang Zou +14 more
doaj +3 more sources
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial [PDF]
American Journal of Respiratory and Critical Care Medicine, 2020 Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the ...
yves Dauvilliers +2 more
exaly +5 more sources
Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety [PDF]
Pharmacology Research and PerspectivesPitolisant, a novel histamine H3‐receptor antagonist, holds significant promise for treating narcolepsy. However, a petition, which highlighted that pitolisant was associated with deaths during clinical trials, has propelled it into the spotlight of ...
Cheng Jiang +5 more
exaly +3 more sources
Update on the treatment of narcolepsy: clinical efficacy of pitolisant
Nature and Science of Sleep, 2017 Michael W Calik1,2 1Department of Biobehavioral Health Science, 2Center for Narcolepsy, Sleep and Health Research, University of Illinois at Chicago, Chicago, IL, United States Abstract: Narcolepsy is a neurological disease that affects 1 in 2,000 ...
Calik MW
doaj +6 more sources
0755 Pitolisant (Wakix) is an Effective Anti-Cataplexy Agent in Narcolepsy Type 1 [PDF]
Drugs, 2020 Pitolisant (Wakix™) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject. Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults. Pitolisant has received a Temporary Authorization of Use in France for this indication in case of treatment failure, intolerance or ...
Gerard Meskill
+7 more sources
Pitolisant Hydrochloride (Wakix)
Canadian Journal of Health Technologies, 2022 CADTH recommends that Wakix not be reimbursed by public drug plans for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. It is still not known whether Wakix offers any therapeutic benefit over other treatments used for EDS or cataplexy.
CADTH
openalex +3 more sources
Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects [PDF]
Medicines, 2020 Background: Besides its well-known role as a peripheral chemical mediator of immune, vascular, and cellular responses, histamine plays major roles in the central nervous system, particularly in the mediation of arousal and cognition-enhancement.
Victoria Harwell, Pius S. Fasinu
doaj +2 more sources
Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review [PDF]
Cureus, 2021 Narcolepsy is characterized by excessive daytime sleepiness (EDS) and cataplexy. Histamine neurons play an important role in enhancing wakefulness. The objective of our study was to evaluate the efficacy of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist, in patients with a high burden of narcolepsy symptoms. We conducted an advanced
Stephanie P Fabara +6 more
openalex +3 more sources